An interventional study of Back Exosuit in Low Back Pain, Musculoskeletal Pain and Low Back Injury, sponsored by Wyss Institute at Harvard University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Wyss Institute at Harvard University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.
Among the 712 studies in Low Back Pain with a site in United States, this one is the 282nd largest by enrollment of the 623 interventional ones that give a count, is one of 23 that started in 2023, is one of 408 with no phase, and was the 588th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
New York Medical College · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–65 · Healthy volunteers
University of Central Florida · Sites in United States
Ages 18–65
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
712 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 80 · Phase 3 73 · Phase 4 50
First in 1977; this study’s year is marked. 23 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 79 across the 623 interventional studies, 90 across the 85 observational. Of the 513 that completed or were terminated, 207 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 712 have an industry lead sponsor. The 10 most frequent:
Wyss Institute at Harvard University is the lead sponsor of 5 studies on the registry; none are open to participants now.
Wyss Institute at Harvard University has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
52 of the studies in Low Back Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT07652944Joe X. ZhangTrial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain. | 2026-11 |
| NCT04730700University of Kansas Medical CenterEvaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. | 2026-11-30 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 52 to your calendar (.ics) → With an account.
Among the 712 studies in Low Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine if a wearable back exosuit can make it safer and easier for workers who bend, lift, and lower objects in an industrial setting.
Many studies have shown that wearable back exoskeletons or exosuits can provide helpful forces making a person's back muscles work less. It is believed that exosuits can lower a person's level of workplace effort and fatigue, making it less likely for them to have back pain at work. Back exosuits could be a solution to make a job easier, but how well they work in the real-world over a long period of time is unclear.
The investigators want to know if workers who wear a back exosuit during the workday will have lower rates of lower back pain or injury than those who are not wearing a back exosuit. The investigators also want to know how well exosuit technology integrates into the workplace (for example, how this technology improves or hinders job performance).
Participants will be randomized into an exosuit group or control group. Participants in the exosuit group will be given a back exosuit that they can use as much as they want at work. All participants will complete surveys monthly.
Researchers will compare the exosuit group to the control group to see if using a back exosuit in a workplace can reduce a person's risk and impact of low back injury or pain. The investigators also want to see if a back exosuit impacts job productivity and if participants find the exosuit becomes useful or bothersome over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Exosuit refers to a soft active back exosuit. Participants in the exosuit arm will be fitted to a personal back exosuit device. Participants will be trained on how to use the device (retrieval, donning, powering up, mode switching, and doffing). Participants will be instructed to use the device at work, emphasizing they wear it whenever it seems practical (e.g. lifting) for as long as it remains comfortable. Associates from Verve Motion will check in with exosuit participants to address comfort issues and help participants integrate the exosuit into their workday.
Device: Back Exosuit
Control participants will not be assigned a back exosuit. Participants in the control group will perform workplace tasks as normal, completing study surveys at baseline and monthly for 4 months that are identical to exosuit group.
The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
Also known as: Verve SafeLift Suit
Level of Work-interfering Low Back Pain (Changes Over Time and Differences Between Groups)
The Cornell Musculoskeletal Discomfort Questionnaire (MDQ) is a composite score that ranges from 0-90. The score is calculated by multiplying a perceived rating frequency, severity, and work interference of body discomfort with higher scores corresponding to higher overall discomfort. The back discomfort score will be evaluated between the 2 groups at 5 time points.
Time frame: Baseline, Months (1-4)
Self-reported Incidence of Low Back Pain (Changes Over Time and Differences Between Groups)
The incidence of a workplace low back discomfort event was defined as a \> 6-point increase in a participant's lower back MDQ (reference in outcome 1) relative to their last recorded survey. If an incidence of low back discomfort is recorded the affirmative status is carried forward into subsequent completed surveys.
Time frame: Months (1-4)
Self-reported Severity of Low Back Pain (Changes Over Time and Differences Between Groups)
Back pain severity refers to the level of intensity and the occupational or medical consequence of back pain. The following self-report measures will determine these values. Numerical rating scale of back pain, which ranges from 0-10 where the highest score 10 represents a participants worst pain imaginable.
Time frame: Baseline, Months (1-4)
Self-reported Intensity of Global Pain (Changes Over Time and Differences Between Groups)
Beyond low back pain, participants will report on total body discomfort and the intensity of discomfort at various joints: Total body discomfort and interference will be evaluated using the Pain, Enjoyment of Lift and General Activity (PEG) 3 Scale, which ranges from 0-10. A higher score indicates greater pain intensity and greater interference with enjoyment of life and everyday activity.
Time frame: Baseline, Months (1-4)
Self-reported Intensity of Localized Body Discomfort (Changes Over Time and Differences Between Groups)
The Cornell MSD scale (reference in outcome 1) will also be evaluated at every other body part (for example, ankles, knees, hip, upper back, neck, shoulders, elbows, and wrists). The composite score represents the sum (total) of all scores across 9 body parts, and ranges from 0-810. A higher score indicates higher intensity, and frequency of work interfering discomfort for multiple body parts.
Time frame: Baseline, Months (1-4)
Self-reported Perception of Effort (Changes Over Time and Differences Between Groups)
A modified BORG scale has been developed with questions focusing on perceived level of back exertion. The scale ranges from 0-100, where a higher score indicates higher perceived back effort (maximal effort).
Time frame: Baseline, Months (1-4)
Self-reported Perception of Physical Fatigue (Changes Over Time and Differences Between Groups)
A modified BORG scale has been developed with questions focusing on perceived level of workplace fatigue. The scale ranges from 0-100, where a higher score indicates higher perceived physical fatigue (absolutely exhausted).
Time frame: Baseline, Months 1-4
| Milestone | Exosuit | Control |
|---|---|---|
| Started | 64 | 31 |
| Completed | 46 | 26 |
| Not completed | 18 | 5 |
The Cornell Musculoskeletal Discomfort Questionnaire (MDQ) is a composite score that ranges from 0-90. The score is calculated by multiplying a perceived rating frequency, severity, and work interference of body discomfort with higher scores corresponding to higher overall discomfort. The back discomfort score will be evaluated between the 2 groups at 5 time points.
| Scores on a scale | Exosuit | Control |
|---|---|---|
| Baseline | 2.1 ± 4.5 | 2.5 ± 4.6 |
| Survey 1 | 1.2 ± 3.0 | 2.5 ± 5.6 |
| Survey 2 | 1.3 ± 2.8 | 3.1 ± 8.3 |
| Survey 3 | 1.0 ± 3.0 | 2.0 ± 4.5 |
| Survey 4 | 2.0 ± 4.4 | 3.2 ± 8.2 |
The incidence of a workplace low back discomfort event was defined as a \> 6-point increase in a participant's lower back MDQ (reference in outcome 1) relative to their last recorded survey. If an incidence of low back discomfort is recorded the affirmative status is carried forward into subsequent completed surveys.
| Participants | Exosuit | Control |
|---|---|---|
| Survey 1 | 1 | 1 |
| Survey 2 | 2 | 3 |
| Survey 3 | 2 | 4 |
| Survey 4 | 3 | 6 |
Back pain severity refers to the level of intensity and the occupational or medical consequence of back pain. The following self-report measures will determine these values. Numerical rating scale of back pain, which ranges from 0-10 where the highest score 10 represents a participants worst pain imaginable.
| Scores on a scale | Exosuit | Control |
|---|---|---|
| Baseline | 1.8 ± 2.6 | 1.2 ± 2.3 |
| Survey 1 | 1.0 ± 2.0 | 1.6 ± 2.6 |
| Survey 2 | 1.3 ± 2.3 | 1.7 ± 2.3 |
| Survey 3 | 0.9 ± 1.9 | 1.1 ± 2.1 |
| Survey 4 | 1.0 ± 2.2 | 1.5 ± 2.2 |
Beyond low back pain, participants will report on total body discomfort and the intensity of discomfort at various joints: Total body discomfort and interference will be evaluated using the Pain, Enjoyment of Lift and General Activity (PEG) 3 Scale, which ranges from 0-10. A higher score indicates greater pain intensity and greater interference with enjoyment of life and everyday activity.
| Scores on a scale | Exosuit | Control |
|---|---|---|
| Baseline | 1.9 ± 2.2 | 1.6 ± 2.0 |
| Survey 1 | 1.5 ± 2.2 | 1.8 ± 2.3 |
| Survey 2 | 1.3 ± 2.1 | 1.9 ± 2.5 |
| Survey 3 | 1.0 ± 2.1 | 1.5 ± 2.1 |
| Survey 4 | 1.2 ± 2.2 | 1.4 ± 2.1 |
The Cornell MSD scale (reference in outcome 1) will also be evaluated at every other body part (for example, ankles, knees, hip, upper back, neck, shoulders, elbows, and wrists). The composite score represents the sum (total) of all scores across 9 body parts, and ranges from 0-810. A higher score indicates higher intensity, and frequency of work interfering discomfort for multiple body parts.
| Scores on a scale | Exosuit | Control |
|---|---|---|
| Baseline | 20.9 ± 30.4 | 15.7 ± 20.6 |
| Survey 1 | 12.7 ± 23.4 | 16.6 ± 24.6 |
| Survey 2 | 11.8 ± 21.5 | 20.7 ± 35.9 |
| Survey 3 | 14.5 ± 37.4 | 15.3 ± 20.3 |
| Survey 4 | 17.1 ± 34.1 | 15.3 ± 21.6 |
A modified BORG scale has been developed with questions focusing on perceived level of back exertion. The scale ranges from 0-100, where a higher score indicates higher perceived back effort (maximal effort).
| Scores on a scale | Exosuit | Control |
|---|---|---|
| Baseline | 50.7 ± 17.2 | 51.7 ± 18.6 |
| Survey 1 | 46.5 ± 19.9 | 54.1 ± 20.3 |
| Survey 2 | 44.8 ± 20.2 | 51.1 ± 24.6 |
| Survey 3 | 42.6 ± 20.1 | 45.9 ± 19.6 |
| Survey 4 | 46.8 ± 19.9 | 38.0 ± 18.0 |
A modified BORG scale has been developed with questions focusing on perceived level of workplace fatigue. The scale ranges from 0-100, where a higher score indicates higher perceived physical fatigue (absolutely exhausted).
| Scores on a scale | Exosuit | Control |
|---|---|---|
| Baseline | 49.8 ± 18.6 | 48.4 ± 23.5 |
| Survey 1 | 34.8 ± 22.7 | 38.9 ± 23.5 |
| Survey 2 | 37.3 ± 20.8 | 40.8 ± 23.1 |
| Survey 3 | 35.5 ± 22.0 | 42.4 ± 23.6 |
| Survey 4 | 40.1 ± 24.6 | 34.3 ± 18.9 |
Collected over From randomization until the final survey (approximately 21.5+/-1 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Exosuit | 0/64 (0%) | 1/64 (1.6%) | 50/64 (78.1%) |
| Control | 0/31 (0%) | 2/31 (6.5%) | 20/31 (64.5%) |
| Event | Exosuit | Control |
|---|---|---|
| Unrelated eventGeneral disorders | 1/64 | 2/31 |
| Event | Exosuit | Control |
|---|---|---|
| Dermatological and Cutaneous IssuesSkin and subcutaneous tissue disorders | 44/64 | 15/31 |
| Balance DisruptionInjury, poisoning and procedural complications | 29/64 | 8/31 |
| Work Interfering Body DiscomfortInjury, poisoning and procedural complications | 6/64 | 5/31 |
Total enrollment was 97. Two were excluded. Ninety-five were analyzed at baseline.
| Age, Continuous(years) | Exosuit | Control | Total |
|---|---|---|---|
| Mean | 36 ± 12.21 | 35.81 ± 12.39 | 35.89 ± 12.21 |
| Sex: Female, Male(Participants) | Exosuit | Control | Total |
|---|---|---|---|
| Female | 24 | 10 | 34 |
| Male | 40 | 21 | 61 |
| Race (NIH/OMB)(Participants) | Exosuit | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 17 | 7 | 24 |
| White | 42 | 21 | 63 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Exosuit | Control | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 2 | 9 |
| Not Hispanic or Latino | 57 | 29 | 86 |
| Unknown or Not Reported | 0 | 0 | 0 |
| History of Low Back Pain(Participants) | Exosuit | Control | Total |
|---|---|---|---|
| Yes | 15 | 7 | 22 |
| No | 49 | 24 | 73 |
| Job Tenure(Participants) | Exosuit | Control | Total |
|---|---|---|---|
| New Hire | 3 | 2 | 5 |
| Not New Hire | 61 | 29 | 90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data collected in this study are part of the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative. As part of the Back Pain Consortium (BACPAC) data form this study will be submitted to the Data Integration, Algorithm Development and Operations Management Center (DAC) following study completion. Researchers will have the possibility to request data from the DAC.
Time frame: Data will be uploaded to the DAC approximately 6 months to 1 year at study completion. Data may be stored in the DAC indefinitely.
Access criteria: Formal approval from the BACPAC DAC.
Ran from Feb 2023 to primary completion in Apr 2025, 26 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 26 months is above that.
Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2024 → Apr 2025 and completion Sep 2024 → Apr 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wyss Institute at Harvard University